Trials / Completed
CompletedNCT01456663
A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects
A Single-dose, Open-label, Parallel Study to Assess the Pharmacokinetics of AFQ056 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the pharmacokinetics of AFQ056 in subjects with mild, moderate, severe hepatic impairment compared with healthy control subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AFQ056 |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2011-10-21
- Last updated
- 2020-12-08
Locations
3 sites across 3 countries: United States, Germany, Hungary
Source: ClinicalTrials.gov record NCT01456663. Inclusion in this directory is not an endorsement.